scholarly journals Infectious complications after allogeneic hematopoietic stem cell transplantation in children in a bone marrow transplant unit in Colombia

2020 ◽  
Author(s):  
Ana Milena Bravo ◽  
Jailer Arango ◽  
Oscar Ramirez ◽  
Carlos Andres Portilla ◽  
Pio López ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Bone Marrow Transplant ◽  
Hematopoietic Stem Cell ◽  
Marrow Transplant ◽  
Infectious Complications ◽  
Hematopoietic Stem

scholarly journals Challenges and strategies used to increase the report of Brazilian Hematopoietic Stem Cell Transplantation (HSCT) data to the Center for International Blood and Marrow Transplant Research (CIBMTR)

JBMTCT ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 46-52
Author(s):  
Cinthya Corrêa Da Silva ◽  
Heliz Regina Alves das Neves ◽  
Anderson João Simione ◽  
Bruna Letícia da Silva Santos Geraldo ◽  
Eliana Cristina Martins Miranda ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Online Teaching ◽  
Marrow Transplant ◽  
Hematopoietic Stem ◽  
Blood And Marrow Transplant

To increase the report of Brazilian hematopoietic stem cell transplantation (HSCT) data to the Center for International Blood and Marrow Transplant Research (CIBMTR), the Data Managers Working Group (GTGD) of the Brazilian Society of Bone Marrow Transplants (SBTMO), and the Sao Paulo State Bone Marrow Association (AMEO) developed several strategies since 2016: training data managers (GDs) in national and international HSCT meetings, the development of a free online teaching course (EAD) in Portuguese on Transplant Essential Data (TED), on­line and presential training course for new data managers offered by AMEO, the approval by the National Committee of Ethics in Research (CONEP) of a national multicenter protocol to formalize sharing data of Brazilian transplants with the CIBMTR, and the first multicenter eval­uation our HSCT results using the CIBMTR Data Back to Center. The contract between SBTMO and CIBMTR was signed in 2019 and GTGD of the SBTMO was officially created. These actions resulted in an increase from 24 to 41 transplant centers registered at the CIBMTR from 2016 to 2019. The process of increasing adherence and continuity of HSCT reports to the CIBMTR is complex and requires commitment of all professionals involved HSCT. The success of this process depends on education of the GD and the involvement of all HSCT directors.

scholarly journals ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN FANCONI ANEMIA; A SINGLE CENTRE EXPERIENCE

2021 ◽  
Vol 71 (1) ◽  
pp. 190-95
Author(s):  
Tariq Azam Khattak ◽  
Muhammad Farhan ◽  
Tariq Ghafoor ◽  
Tariq Mehmood Satti ◽  
Qamar Un Nisa Chaudhry ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Overall Survival ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Bone Marrow Transplant ◽  
Fanconi Anemia ◽  
Marrow Transplant ◽  
Hematopoietic Stem

Objective: To determine the treatment outcome of Hematopoietic stem cell transplantation in Fanconi Anemia. Study Design: Case series. Place and Duration of Study: Armed Forces Bone Marrow Transplant Center, Rawalpindi, from Jan 2001 to Jun 2018. Methodology: Data of all Fanconi anemia patients who had fully HLA matched bone marrow transplant during this period was analysed for variables affecting the outcome in terms of overall survival. Those fanconi anemia patients who had myelodysplastic changes or acute myeloid leukemia were excluded. Results: Total 27 patients underwent fully HLA matched allogeneic bone marrow transplant for Fanconi Anemia. Mean age of patients at transplant was 12.12 ± 5.16 years. All patients at transplant were in aplastic phase. Conditioning was done with fludarabine 120mg/m2 , ATG 20 mg/kg and Cyclophosphamide at a dose of 20-40 mg/kg. Mean time to neutrophil engraftment was 12.3 ± 2.92days and for platelets 20 ± 10.3 days. Major posttransplant complications were neutropenic fever in 26 (96%), hypertension in 18 (66.6%), mucositis in 12 (44.4%), azotaemia in 8 (29.6%), gut toxicity in 7 (25.9%) and haemorrhagic cystitis in 5 (18.5%) patients. Four patients (14.8%) had acute graft versus host disease while 7 (26%) patients had chronic GVHD. Overall survival at 6 months, 1, 5 and 8 years was 67%, 63%, 59% and 55% respectively. While overall survival in patients transplanted at younger age (<11 years) was 81.8% compared to 37.5% in older age group (>11years) and was statistically significant (p-value = 0.03). Conclusion: Our study demonstrated...................

scholarly journals ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ADULT PATIENTS WITH FANCONI ANEMIA.

2016 ◽  
Vol 8 ◽  
pp. 2016054 ◽  
Author(s):  
Hosein Kamranzadeh fumani ◽  
Mohammad Zokaasadi ◽  
Amir Kasaeian ◽  
Kamran Alimoghaddam ◽  
Asadollah Mousavi ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Fanconi Anemia ◽  
Bone Marrow Failure ◽  
Term Survival ◽  
Hematopoietic Stem

Background & objectives: Fanconi anemia (FA) is a rare genetic disorder caused by an impaired DNA repair mechanism which leads to an increased tendency toward malignancies and progressive bone marrow failure. The only curative management available for hematologic abnormalities in FA patients is hematopoietic stem cell transplantation (HSCT). This study aimed to evaluate the role of HSCT in FA patients.Methods: Twenty FA patients with ages of 16 or more who underwent HSCT between 2002 and 2015 enrolled in this study. All transplants were allogeneic and the stem cell source was peripheral blood and all patients had a full HLA-matched donor.Results: Eleven patients were female and 9 male (55% and 45%). Mean age was 24.05 years. Mortality rate was 50% (n=10) and the main cause of death was GVHD. Survival analysis showed an overall 5-year survival of 53.63% and 13 year survival of 45.96 % among patients.Conclusion: HSCT is the only curative management for bone marrow failure in FA patients and despite high rate of mortality and morbidity it seems to be an appropriate treatment with an acceptable long term survival rate for adolescent and adult group.

Sign in / Sign up

Export Citation Format

Share Document